{"filing":{"accession_number":"0001193125-26-302608","cik":"0001395937","ticker":"SNDX","company_name":"Syndax Pharmaceuticals Inc","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"sndx-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/sndx-20260714.htm"},"events":[{"id":17762,"run_id":15927,"accession_number":"0001193125-26-302608","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Syndax disclosed an R\u0026D event on July 14, 2026, highlighting late-stage programs and unveiling two new pipeline assets: SNDX-4321 (a novel allosteric EGFR inhibitor for NSCLC with IND submission expected by end of 2026 and Phase 1 initiation in 2027) and SNDX-62122 (a next-generation menin inhibitor for myelofibrosis with IND submission and Phase 1 expected in 2027). This represents a material strategic expansion of the company's pipeline with new differentiated assets supported by preclinical data, which would affect a reasonable investor's assessment of the company's R\u0026D capabilities and growth opportunities. The event is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16355,"accession_number":"0001193125-26-302608","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Syndax disclosed an R\u0026D event on July 14, 2026, highlighting late-stage programs and unveiling two new pipeline assets: SNDX-4321 (a novel allosteric EGFR inhibitor for NSCLC with IND submission expected by end of 2026 and Phase 1 initiation in 2027) and SNDX-62122 (a next-generation menin inhibitor for myelofibrosis with IND submission and Phase 1 expected in 2027). This represents a material strategic expansion of the company's pipeline with new differentiated assets supported by preclinical data, which would affect a reasonable investor's assessment of the company's R\u0026D capabilities and growth opportunities. The event is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T12:31:43.927974+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16355,"accession_number":"0001193125-26-302608","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Syndax disclosed an R\u0026D event on July 14, 2026, highlighting late-stage programs and unveiling two new pipeline assets: SNDX-4321 (a novel allosteric EGFR inhibitor for NSCLC with IND submission expected by end of 2026 and Phase 1 initiation in 2027) and SNDX-62122 (a next-generation menin inhibitor for myelofibrosis with IND submission and Phase 1 expected in 2027). This represents a material strategic expansion of the company's pipeline with new differentiated assets supported by preclinical data, which would affect a reasonable investor's assessment of the company's R\u0026D capabilities and growth opportunities. The event is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T12:31:43.927974+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-07-14"}]}